scispace - formally typeset
Search or ask a question

Showing papers by "Beverly L. Davidson published in 2013"


Journal ArticleDOI
TL;DR: It is found that the aptamer library employed here required more than 15 rounds of in vivo selection for convergence to specific sequences, so the methods described may find general utility for targeting various payloads to the brain.
Abstract: The physiological barriers of the brain impair drug delivery for treatment of many neurological disorders. One delivery approach that has not been investigated for their ability to penetrate the brain is RNA-based aptamers. These molecules can impart delivery to peripheral tissues and circulating immune cells, where they act as ligand mimics or can be modified to carry payloads. We developed a library of aptamers and an in vivo evolution protocol to determine whether specific aptamers could be identified that would home to the brain after injection into the peripheral vasculature. Unlike biopanning with recombinant bacteriophage libraries, we found that the aptamer library employed here required more than 15 rounds of in vivo selection for convergence to specific sequences. The aptamer species identified through this approach bound to brain capillary endothelia and penetrated into the parenchyma. The methods described may find general utility for targeting various payloads to the brain.

163 citations


Journal ArticleDOI
TL;DR: A differential effect of human APOE isoforms on amyloid deposition and clearance in transgenic mice and, more importantly, on Aβ-mediated synaptotoxicity is shown, suggesting that the APOE genetic risk is mediated by Aβ, and that therapeutic approaches aimed at decreasing APOE4, or increasing APOE2, may be beneficial in AD.
Abstract: Inheritance of the e4 allele of apolipoprotein E ( APOE ) is the strongest genetic risk factor associated with the sporadic form of Alzheimer’s disease (AD), whereas the rare APOE e2 allele has the opposite effect However, the mechanisms whereby APOE confers risk and protection remain uncertain We used a gene transfer approach to bathe the cortex of amyloid plaque–bearing transgenic mice with virally expressed human APOE We monitored amyloid-β (Aβ) with multiphoton imaging, in vivo microdialysis, and postmortem array tomography to study the kinetics of human APOE-mediated changes in Aβ-related neurotoxicity in a mouse model of AD We observed that human APOE4 increased the concentrations of oligomeric Aβ within the interstitial fluid and exacerbated plaque deposition; the converse occurred after exposure to human APOE2 Peri-plaque synapse loss and dystrophic neurites were also worsened by APOE4 or attenuated by APOE2 Egress of Aβ from the central nervous system (CNS) into the plasma was diminished by APOE3 and APOE4 compared to APOE2, in accord with isoform-specific retention of Aβ in the CNS Overall, our data show a differential effect of human APOE isoforms on amyloid deposition and clearance in transgenic mice and, more importantly, on Aβ-mediated synaptotoxicity These results suggest that the APOE genetic risk is mediated by Aβ, and that therapeutic approaches aimed at decreasing APOE4, or increasing APOE2, may be beneficial in AD

141 citations


Journal ArticleDOI
TL;DR: These findings support the preclinical development of molecular therapies aimed at halting the expression of ATXN3 as a viable approach toSCA3 and point to microRNA deregulation as a potential surrogate marker of SCA3 pathogenesis.

101 citations


Journal ArticleDOI
TL;DR: It is suggested that targeting a large extent of the cerebellum alone may not be sufficient for effective human therapy, and artificial miRNAs or other nucleotide-based suppression strategies targeting ATXN3 more widely in the brain should be considered in future preclinical tests.

96 citations


Journal ArticleDOI
TL;DR: The accumulation of SUMO-2-modified proteins in the insoluble fraction of HD postmortem striata implicates SUMO -2 modification in the age-related pathogenic accumulation of mutant HTT and other cellular proteins that occurs during HD progression.

94 citations


Journal ArticleDOI
TL;DR: Mice treated with AAV4-BDNF/noggin or with BDNF and noggin proteins actively recruited subependymal progenitor cells to form new MSNs that matured and achieved circuit integration and may represent a promising avenue for disease amelioration in HD.

59 citations


Journal ArticleDOI
TL;DR: It is proposed that CLN3 facilitates TGN-to-plasma membrane transport of microdomain-associated proteins in brain endothelial cells and localizes to the trans-Golgi network (TGN) and partitions with buoyant microdomain fractions.
Abstract: Juvenile neuronal ceroid lipofuscinosis (JNCL) is a fatal childhood-onset neurodegenerative disorder caused by mutations in ceroid lipofuscinosis neuronal-3 (CLN3), a hydrophobic transmembrane protein of unresolved function. Previous studies indicate blood–brain barrier (BBB) defects in JNCL, and our earlier report showed prominent Cln3 expression in mouse brain endothelium. Here we find that CLN3 is necessary for normal trafficking of the microdomain-associated proteins caveolin-1, syntaxin-6, and multidrug resistance protein 1 (MDR1) in brain endothelial cells. Correspondingly, CLN3-null cells have reduced caveolae, and impaired caveolae- and MDR1-related functions including endocytosis, drug efflux, and cell volume regulation. We also detected an abnormal blood–brain barrier response to osmotic stress in vivo. Evaluation of the plasma membrane with fluorescent sphingolipid probes suggests microdomain destabilization and enhanced fluidity in CLN3-null cells. In further work we found that application of the glycosphingolipid lactosylceramide to CLN3-deficient cells rescues protein transport and caveolar endocytosis. Last, we show that CLN3 localizes to the trans-Golgi network (TGN) and partitions with buoyant microdomain fractions. We propose that CLN3 facilitates TGN-to-plasma membrane transport of microdomain-associated proteins. Insult to this pathway may underlie BBB dysfunction and contribute to JNCL pathogenesis.

57 citations


Journal ArticleDOI
TL;DR: A specificity-focused siRNA design algorithm and accompanying online tool which, upon validation, identifies candidate sequences with minimal off-targeting potentials and potent silencing capacities and provides the only broadly applicable means to limit off- targeting from RNAi expression vectors.
Abstract: RNA interference (RNAi) serves as a powerful and widely used gene silencing tool for basic biological research and is being developed as a therapeutic avenue to suppress disease-causing genes. However, the specificity and safety of RNAi strategies remains under scrutiny because small inhibitory RNAs (siRNAs) induce off-target silencing. Currently, the tools available for designing siRNAs are biased toward efficacy as opposed to specificity. Prior work from our laboratory and others’ supports the potential to design highly specific siRNAs by limiting the promiscuity of their seed sequences (positions 2–8 of the small RNA), the primary determinant of off-targeting. Here, a bioinformatic approach to predict off-targeting potentials was established using publically available siRNA data from more than 50 microarray experiments. With this, we developed a specificity-focused siRNA design algorithm and accompanying online tool which, upon validation, identifies candidate sequences with minimal off-targeting potentials and potent silencing capacities. This tool offers researchers unique functionality and output compared with currently available siRNA design programs. Furthermore, this approach can greatly improve genome-wide RNAi libraries and, most notably, provides the only broadly applicable means to limit off-targeting from RNAi expression vectors.

51 citations


Journal ArticleDOI
TL;DR: Delivery of either ataxin-1-like or miS1 viral vectors to SCA1 mice cerebella resulted in widespread cerebellar Purkinje cell transduction and improved behavioral and histological phenotypes, indicating the utility of either approach as a possible therapy for SCA2 patients.

44 citations


Journal ArticleDOI
TL;DR: The ability to reliably conduct loss-of-function assays in polarized primary airway epithelia offers benefits to research in studies of epithelial cell homeostasis, candidate gene function, gene-based therapeutics, microRNA biology, and targeting the replication of respiratory viruses.
Abstract: Polarized and pseudostratified primary airway epithelia present barriers that significantly reduce their transfection efficiency and the efficacy of RNA interference oligonucleotides. This creates an impediment in studies of the airway epithelium, diminishing the utility of loss-of-function as a research tool. Here we outline methods to introduce RNAi oligonucleotides into primary human and porcine airway epithelia grown at an air-liquid interface and difficult-to-transfect transformed epithelial cell lines grown on plastic. At the time of plating, we reverse transfect small-interfering RNA (siRNA), Dicer-substrate siRNA, or microRNA oligonucleotides into cells by use of lipid or peptide transfection reagents. Using this approach we achieve significant knockdown in vitro of hypoxanthine-guanine phosphoribosyltransferase, IL-8, and CFTR expression at the mRNA and protein levels in 1–3 days. We also attain significant reduction of secreted IL-8 in polarized primary pig airway epithelia 3 days posttransfection and inhibition of CFTR-mediated Cl− conductance in polarized air-liquid interface cultures of human airway epithelia 2 wk posttransfection. These results highlight an efficient means to deliver RNA interference reagents to airway epithelial cells and achieve significant knockdown of target gene expression and function. The ability to reliably conduct loss-of-function assays in polarized primary airway epithelia offers benefits to research in studies of epithelial cell homeostasis, candidate gene function, gene-based therapeutics, microRNA biology, and targeting the replication of respiratory viruses.

41 citations


Journal ArticleDOI
TL;DR: A significant alteration in the steady-state levels of numerous miRNAs prior to and following phenotypic onset is found and there is evidence that increased miR-150 levels in SCA1 Purkinje neurons may modulate disease pathogenesis by targeting the expression of Rgs8 and Vegfa.

Journal ArticleDOI
TL;DR: It is shown that delivery of DN:REST in the motor cortex restores brain-derived neurotrophic factor mRNA and protein levels by reducing endogenous REST occupancy at the Bdnf locus and suggests that a more widespread rescue of REST-regulated sites in the affected brain regions may be necessary.
Abstract: In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice

Journal ArticleDOI
TL;DR: Recent progress on RNA interference-based therapies in various model systems is reviewed and outstanding questions or concerns that have emerged as a result of an improved (and ever advancing) understanding of the technologies employed are highlighted.

Patent
14 Mar 2013
TL;DR: In this paper, the authors presented methods of delivering a protective ApoE isoform to the central nervous system of a mammal, comprising administering to the cerebrospinal fluid (CSF) of the mammal an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding the protective apoEisoform inserted between a pair of AAV inverted terminal repeats.
Abstract: The present disclosure provides methods of delivering a protective ApoE isoform to the central nervous system of a mammal, comprising administering to the cerebrospinal fluid (CSF) of the mammal an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding the protective ApoE isoform inserted between a pair of AAV inverted terminal repeats in a manner effective to infect ependymal cells in the non-rodent mammal such that the ependymal cells secrete the ApoE into the CSF of the mammal.

Patent
14 Mar 2013
TL;DR: An adeno-associated virus filler component comprising a nucleic acid of between 3300 and 4200 nucleotides in length is described in this article, where the filler is used to replace the original virus.
Abstract: An adeno-associated virus filler component comprising a nucleic acid of between 3300 and 4200 nucleotides in length is disclosed.

Patent
14 Mar 2013
TL;DR: In this paper, the authors proposed methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contact with a therapeutic RNAi agent.
Abstract: The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent.


Patent
18 Sep 2013
TL;DR: In this paper, a safe and effective way to deliver and express therapeutic compositions (e.g., transgenes) to the pancreas and lungs of a mammal was proposed.
Abstract: The present invention relates to a safe and effective way to deliver and express therapeutic compositions (e.g., transgenes) to the pancreas and lungs of a mammal.